Abstract
Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Current Molecular Medicine
Title: Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Volume: 9 Issue: 6
Author(s): Sarah Church, Bernard A. Fox, Walter J. Urba, Brendan D. Curti, Hong-Ming Hu, Todd S. Crocenzi, Sidney Rosenheim, Andrew D. Weinberg, Emmanuel Akporiaye, Edwin B. Walker, Daniel P. Haley, Elisa Cardenas, Ulf Petrausch, Kevin Friedman, Levi Maston, Tarsem Moudgil, Michael G. LaCelle, Sachin Puri, Ilka Assmann, James A. Thompson, Chris Twitty, Shawn M. Jensen and Christian H. Poehlein
Affiliation:
Abstract: Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Export Options
About this article
Cite this article as:
Church Sarah, Fox A. Bernard, Urba J. Walter, Curti D. Brendan, Hu Hong-Ming, Crocenzi S. Todd, Rosenheim Sidney, Weinberg D. Andrew, Akporiaye Emmanuel, Walker B. Edwin, Haley P. Daniel, Cardenas Elisa, Petrausch Ulf, Friedman Kevin, Maston Levi, Moudgil Tarsem, LaCelle G. Michael, Puri Sachin, Assmann Ilka, Thompson A. James, Twitty Chris, Jensen M. Shawn and Poehlein H. Christian, Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970670
DOI https://dx.doi.org/10.2174/156652409788970670 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and NAD+ in Ischemic Brain Injury: Current Advances and Future Perspectives
Current Medicinal Chemistry 5-Lipoxygenase in the Central Nervous System: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders
Current Pharmaceutical Design Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets The Role of 18 kDa Mitochondrial Translocator Protein (TSPO) in Programmed Cell Death, and Effects of Steroids on TSPO Expression
Current Molecular Medicine Novel Therapeutic Approaches Targeting Vascular Endothelial Growth Factor and its Receptors in Haematological Malignancies
Current Cancer Drug Targets Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics
Current Pharmacogenomics Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research Notch-Associated MicroRNAs in Cancer
Current Drug Targets Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters Brain Tumor Detection Using Machine Learning and Deep Learning: A Review
Current Medical Imaging Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Current Medicinal Chemistry